INTRODUCTION 21
In the 1990s, health care quality improvement initiatives focused on raising awareness for 22 the problem of inadequately treated pain.
1 After the adoption of new standards for the 23 management of pain, the United States saw an increase in prescribing of opioid analgesics. 24
Between 1997 and 2007, the distribution of opioid drugs increased by over 7 times. 2 Overdoses 25 from prescription opioid pain relievers (OPR) quadrupled between 1999 and 2010. 3 OPR 26 overdoses remains a serious public health problem with 5.6 deaths per 100,000 individuals in 27 2012. 3 A national approach to addressing prescription drug overdoses attempts to "balance the 28 desire to minimize abuse with the need to ensure legitimate access to these medications". 4 One 29 section of this plan calls for the establishment of prescription drug monitoring programs 30 (PDMPs) in all 50 states. A PDMP is a statewide electronic database that collects detailed data 31 on controlled substance prescriptions (CSPs) in a state. 5, 6 PDMPs have proven to be invaluable 32 tools in fighting the prescription drug abuse epidemic by reducing drug diversion of controlled 33 substances and improving clinical decision-making through increased access to detailed patient 34 drug histories.
35
Pharmacists have an important role in the effort to address prescription drug abuse and 36 are the "last line of defense". A recent study suggested that more consistent use of PDMPs by 37 pharmacists resulted in a higher number of refusals to dispense CSPs as a result of greater access 38 to patient information.
8 "Limited access to information affects [outpatient] pharmacists in 39 fundamental ways, most specifically having incomplete prescription information which can leave 40 the pharmacist unable to fill the prescription". 9 Pharmacists' utilization of PDMPs may lead to a 41 decrease in the morbidity and mortality associated with prescription drug abuse. 10 
Utilization of 42
PDMPs in pharmacy practice may be beneficial to reducing the impact of prescription drug 43 Indiana's total pharmacist population. The sample exhibited similar characteristics to Indiana's 66 2012 Pharmacist workforce in regards to age, years practicing, and gender. 8 
67

Study Population 68
The study population included 1,000 outpatient pharmacists who completed the 2012 69 IPLA Knowledge and Use Survey. Pharmacists were considered to be working in an outpatient 70 setting if they reported their primary practice setting as a community health center, diagnostic 71 testing facility, outpatient clinic, outpatient surgery center, pharmacy (outpatient), retail medicine 72 clinic, or an urgent care facility. Otherwise, the pharmacist was excluded from the study. 73
Study Outcomes 74
The study consisted of 2 primary outcome measures. Multiple logistic regression was used to study 2 outcome variables, Used INSPECT and 86
Often Check INSPECT. Variables that were contextually relevant or statistically significant in 87 the bivariate analyses were added to the initial multiple logistic regression models to control for 88 factors that may influence the relationship between the primary outcome measures and the 89 dependent variable. Degree type was not available in these data and so the variable training 90 period was created to control for the time in which the provider was trained in relation to the 91 adoption of the PharmD as the sole entry level degree for the pharmacy profession. 8 Stepwise 92 elimination was used to fit the model and to exclude any variables that had no statistical or 93 conceptual significance in the multivariate model. 13 The study outcome measures were assessed 94 with determination of odds ratio (OR) estimates and 95% Wald confidence intervals (CIs). 95
RESULTS
96
Barriers to INSPECT Utilization 97
Basic demographic information describing the sample population is provided in Table 1 . 98
Although 97% of outpatient pharmacists had heard of INSPECT prior to receiving the survey, 99 only 81% of them reported using it. Furthermore, only 3% of outpatient pharmacists reported 100 using INSPECT at every visit compared to periodically (88%) or never (9%) using INSPECT. 101
All respondents who had heard of INSPECT were asked to report perceived barriers to using the 102 PDMP. The frequency of reported barriers to INSPECT and there association to INSPECT use 103 (relative risk) is included in Table 2 . If a pharmacists reported no barrier, they were 3 times more 104 likely to also report using INSPECT; however, they were significantly less likely to use 105 INSPECT if they reported at least one barrier (RR=.80). Surprisingly, pharmacists who reported 106 being afraid of legal ramifications were the least likely to report using INSPECT (RR=.44). 107
The study also aimed to examine how barriers effect the frequency of INSPECT use. 108 provider's level of concern with prescription drug abuse in the community. These results (Table  116 3) demonstrated that outpatient pharmacists who reported being extremely concerned with 117 prescription drug abuse in the community were approximately 10 times more likely to use 118
INSPECT as compared to those who reported being not at all concerned (OR = 9.96, 95% CI, 119
1.724 -57.536). Not only were those pharmacists extremely concerned with prescription drug 120 abuse in the community more likely to report using INSPECT, but they were 18 times more 121 likely to use INSPECT more frequently than those who were not at all concerned (OR = 17. INSPECT use and also to build awareness within the pharmacy community about prescription 144 drug abuse in order to promote more consistent use of the PDMP. Outpatient pharmacists were 145 10 times more likely to report using INSPECT if they were extremely concerned with 146 prescription drug abuse as compared to those who were not concerned at all. Also, outpatient 147 pharmacists were 18 times more likely to use INSPECT more often if they were extremely 148 concerned as compared to those who were not concerned at all. Therefore, it is possible that 149 building awareness about prescription drug abuse within the pharmacy community may 150 significantly increase the number of pharmacists not only using the PDMP, but using it more 151 frequently. 152
Study Limitations 153
This study was conducted within one state, Indiana. The generalizability of these 154 findings to other states may be a limitation. Furthermore, the response rate for the survey was 155 low and may be a limitation to the study. A previous study compared Indiana's 2012 pharmacist 156
workforce to the survey sample and confirmed the survey sample comparable to Indiana's 157 pharmacist workforce. Another limitation to this study was response bias as the outcome 158 measures were self-reported. It is likely that response bias may result in an overestimate of 159 pharmacists use of INSPECT as well as reported frequency of use. The survey was administered 160 anonymously to limit response bias. In light of these limitations, the study findings should still 161 be considered due to their important implications and consistency with previous literature. 162
CONCLUSION 163
This study concludes that strategies to improve outpatient pharmacists' utilization of 164
PDMPs should look for innovative ways to limit administrative barriers and also build outpatient 165 pharmacists' awareness of prescription drug abuse and misuse within their community. 
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